Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast CancerThomas Hatschek, Jonas Bergh, Theodoros Foukakis et al.|JAMA Oncology|2021Cited by 58
Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 TrialAlexios Matikas, Theodoros Foukakis, Hemming Johansson et al.|Clinical Cancer Research|2022Cited by 41
Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?Jonas Bergh, Thomas Hatschek, Judith Bjöhle et al.|Journal of Clinical Oncology|2019Cited by 21
The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trialYajing Zhu, Theodoros Foukakis, Ioannis Zerdes et al.|Breast Cancer Research and Treatment|2024Cited by 6
97O PREDIX HER2 trial: Event-free survival and pathologic complete response in clinical subgroups and stromal TILs levelsThomas Hatschek, Jonas Bergh, Anne Andersson et al.|Annals of Oncology|2020Cited by 5